168 related articles for article (PubMed ID: 35712496)
1. Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review.
Ishida A; Shichi H; Fukuoka H; Shiramizu H; Inoshita N; Yamada S
Front Oncol; 2022; 12():916982. PubMed ID: 35712496
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay.
Ishida A; Shichi H; Fukuoka H; Inoshita N; Ogawa W; Yamada S
Pituitary; 2022 Apr; 25(2):238-245. PubMed ID: 34773564
[TBL] [Abstract][Full Text] [Related]
3. Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor.
Nakano-Tateno T; Satou M; Inoshita N; van Landeghem FKH; Easaw J; Mehta V; Tateno T; Chik CL
Endocr Pathol; 2021 Sep; 32(3):418-426. PubMed ID: 32833164
[TBL] [Abstract][Full Text] [Related]
4. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Zacharia BE; Gulati AP; Bruce JN; Carminucci AS; Wardlaw SL; Siegelin M; Remotti H; Lignelli A; Fine RL
Neurosurgery; 2014 Apr; 74(4):E447-55; discussion E455. PubMed ID: 24226425
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Thearle MS; Freda PU; Bruce JN; Isaacson SR; Lee Y; Fine RL
Pituitary; 2011 Dec; 14(4):418-24. PubMed ID: 19960369
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.
Kola B; Korbonits M; Diaz-Cano S; Kaltsas G; Morris DG; Jordan S; Metherell L; Powell M; Czirják S; Arnaldi G; Bustin S; Boscaro M; Mantero F; Grossman AB
Clin Endocrinol (Oxf); 2003 Sep; 59(3):328-38. PubMed ID: 12919156
[TBL] [Abstract][Full Text] [Related]
7. Course of Aggressive Somatotroph, Corticotroph and Mammotroph Tumors under Temozolomide; Report of Three Cases and Review of the Literature.
Aydoğan Bİ; Ünlütürk U; Emral R; Güllü S
Turk Neurosurg; 2017 May; ():. PubMed ID: 28608351
[TBL] [Abstract][Full Text] [Related]
8. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
9. A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study.
Wang W; Zhang Y; Peng Y; Jin KZ; Li YL; Liang Y; Tan HY; Yu XJ; Zhou ZW; Chen J
Neuroendocrinology; 2021; 111(8):752-763. PubMed ID: 32668427
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
13. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
14. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature.
Chinezu L; Vasiljevic A; Trouillas J; Lapoirie M; Jouanneau E; Raverot G
Eur J Endocrinol; 2017 Feb; 176(2):195-201. PubMed ID: 27913611
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.
Ben-Shlomo A; Liu NA; Melmed S
Pituitary; 2017 Feb; 20(1):93-99. PubMed ID: 27900635
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior.
Thapar K; Kovacs K; Stefaneanu L; Scheithauer B; Killinger DW; Lioyd RV; Smyth HS; Barr A; Thorner MO; Gaylinn B; Laws ER
Am J Pathol; 1997 Sep; 151(3):769-84. PubMed ID: 9284826
[TBL] [Abstract][Full Text] [Related]
17. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly.
Morin E; Berthelet F; Weisnagel J; Bidlingmaier M; Serri O
Pituitary; 2012 Mar; 15(1):97-100. PubMed ID: 20407837
[TBL] [Abstract][Full Text] [Related]
18. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor.
Thorner MO; Perryman RL; Cronin MJ; Rogol AD; Draznin M; Johanson A; Vale W; Horvath E; Kovacs K
J Clin Invest; 1982 Nov; 70(5):965-77. PubMed ID: 6290540
[TBL] [Abstract][Full Text] [Related]
19. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary.
Yamada S; Sano T; Stefaneanu L; Kovacs K; Aiba T; Sawano S; Shishiba Y
J Clin Endocrinol Metab; 1993 Feb; 76(2):352-6. PubMed ID: 8432778
[TBL] [Abstract][Full Text] [Related]
20. Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.
Ghazi AA; Rotondo F; Kovacs K; Amirbaigloo A; Syro LV; Fathalla H; Di Ieva A; Cusimano MD
Endocr Pathol; 2015 May; 26(2):135-9. PubMed ID: 25716461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
